Identification of epigenome-wide DNA methylation differences between carriers of APOE ε4 and APOE ε2 alleles
Top Cited Papers
Open Access
- 4 January 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Genome Medicine
- Vol. 13 (1), 1-14
- https://doi.org/10.1186/s13073-020-00808-4
Abstract
Background: The apolipoprotein E (APOE) epsilon 4 allele is the strongest genetic risk factor for late onset Alzheimer's disease, whilst the epsilon 2 allele confers protection. Previous studies report differential DNA methylation of APOE between epsilon 4 and epsilon 2 carriers, but associations with epigenome-wide methylation have not previously been characterised. Methods: Using the EPIC array, we investigated epigenome-wide differences in whole blood DNA methylation patterns between Alzheimer's disease-free APOE epsilon 4 (n = 2469) and epsilon 2 (n = 1118) carriers from the two largest single-cohort DNA methylation samples profiled to date. Using a discovery, replication and meta-analysis study design, methylation differences were identified using epigenome-wide association analysis and differentially methylated region (DMR) approaches. Results were explored using pathway and methylation quantitative trait loci (meQTL) analyses. Results: We obtained replicated evidence for DNA methylation differences in a similar to 169 kb region, which encompasses part of APOE and several upstream genes. Meta-analytic approaches identified DNA methylation differences outside of APOE: differentially methylated positions were identified in DHCR24, LDLR and ABCG1 (2.59 x 10(-100) <= P <= 2.44 x 10(-8)) and DMRs were identified in SREBF2 and LDLR (1.63 x 10(-4) <= P <= 3.01 x 10(-2)). Pathway and meQTL analyses implicated lipid-related processes and high-density lipoprotein cholesterol was identified as a partial mediator of the methylation differences in ABCG1 and DHCR24. Conclusions: APOE epsilon 4 vs. epsilon 2 carrier status is associated with epigenome-wide methylation differences in the blood. The loci identified are located in trans as well as cis to APOE and implicate genes involved in lipid homeostasis.Funding Information
- Wellcome Trust (104036/Z/14/Z, 108890/Z/15/Z, 204979/Z/16/Z, 104036/Z/14/Z, 10436/Z/14/Z)
- Medical Research Council (MC_PC_17209)
- Chief Scientist Office, Scottish Government Health and Social Care Directorate (CZD/16/6)
- Brain and Behavior Research Foundation (27404)
- Alzheimer’s Research UK (ARUK-PG2017B-10)
This publication has 70 references indexed in Scilit:
- RegScan: a GWAS tool for quick estimation of allele effects on continuous traits and their combinationsBriefings in Bioinformatics, 2013
- Pedigree and genotyping quality analyses of over 10,000 DNA samples from the Generation Scotland: Scottish Family Health StudyBMC Medical Genetics, 2013
- Apolipoprotein E does not cross the blood-cerebrospinal fluid barrier, as revealed by an improved technique for sampling CSF from miceAmerican Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2012
- Cohort Profile: Generation Scotland: Scottish Family Health Study (GS:SFHS). The study, its participants and their potential for genetic research on health and illnessInternational Journal of Epidemiology, 2012
- GCTA: A Tool for Genome-wide Complex Trait AnalysisAmerican Journal of Human Genetics, 2011
- METAL: fast and efficient meta-analysis of genomewide association scansBioinformatics, 2010
- The effect of APOE genotype on brain levels of oxysterols in young and old human APOE ε2, ε3 and ε4 knock-in miceNeuroscience, 2010
- ABCG1 influences the brain cholesterol biosynthetic pathway but does not affect amyloid precursor protein or apolipoprotein E metabolism in vivoJournal of Lipid Research, 2008
- Effects of Age, Sex, and Ethnicity on the Association Between Apolipoprotein E Genotype and Alzheimer DiseaseJAMA, 1997
- Gene Dose of Apolipoprotein E Type 4 Allele and the Risk of Alzheimer's Disease in Late Onset FamiliesScience, 1993